Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Showing Encouraging Early Data
Quantum BioPharma announced that patient enrollment in its multiple sclerosis imaging study with Massachusetts General Hospital has reached 50%, with preliminary PET imaging data showing promising signals in acute MS lesions and potential sensitivity to gray matter lesions, which could accelerate development of MS therapies including its candidate Lucid-MS.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance the development of MS therapies, including its investigational candidate Lucid-MS.
The milestone is significant because it brings the study closer to validating a new imaging biomarker that could more accurately measure myelin loss and repair. Currently, standard MRI techniques are limited in their ability to detect gray matter lesions or differentiate between various stages of demyelination. If successful, this PET imaging approach could provide a more precise tool for clinical trials, potentially accelerating the development of effective treatments for MS, a chronic neurodegenerative disease affecting millions worldwide.
Quantum BioPharma has submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. The imaging study's results could help inform the design of that trial and provide a more sensitive endpoint for measuring treatment effects.
The company also retains a 19.84% stake in Unbuzzd Wellness Inc., which markets the over-the-counter product UNBUZZD, and is entitled to royalty payments of 7% of sales until $250 million is reached, dropping to 3% in perpetuity thereafter. Quantum retains full rights to develop similar products for pharmaceutical and medical uses, as detailed in the company's press release.
For investors, the midpoint enrollment and promising early data suggest progress in the company's pipeline. The imaging study could de-risk the development of Lucid-MS by providing a more reliable method to assess demyelination, potentially increasing the chances of success in future clinical trials. Further updates are expected as the study continues, and more information is available in the company's newsroom.